Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib in Japanese Patients with APDS
NCT06249997Phase 3Recruiting
- Sponsor
- Pharming Group
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of leniolisib in activated phosphoinositide 3-kinase delta syndrome (APDS), sponsored by Pharming Group. Started Aug 2023; status: recruiting.
02
Drugs
leniolisib
03
Conditions
activated phosphoinositide 3-kinase delta syndrome (APDS)
Beyond the preview
Go deeper on NCT06249997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249997.